Canadian Cancer Trials Group Bulletins


Recent Publications

Canadian Cancer Trials Group MAP.3BSS: Bone Density and Structure in Healthy Postmenopausal Women Treated with Exemestane for the Primary Prevention of Breast Cancer: A Nested Substudy of the MAP.3 Randomized Controlled Trial

Cheung AM, Tile L, Cardew S, Pruthi S, Robbins J, Tomlinson G, Kapral MK, Khosla S, Majumdar S, Erlandson M, Scher J, Hu H, Demaras A, Lickley L, Bordeleau L, Elser C, Ingle J, Richardson H, Goss PE. Bone density and structure in healthy postmenopausal women treated with exemestane for the primary prevention of breast cancer: a nested substudy of the MAP.3 randomised controlled trial (ONLINE). The Lancet Oncology 2012.


Canadian Cancer Trials Group OV.17 (EUDRACT #2004-004456-39) -- A Multi-National, Randomized, Phase III, GCIG Intergroup Study Comparing Pegylated Liposomal Doxorubicin (Caelyx) and Carboplatin vs Paclitaxel and Carboplatin in Patients with Epithelial Ovarian Cancer in Late Relapse (> 6 months): GCIG Calypso Study

Brundage M, Gropp M, Mefti F, Mann K, Lund B, Gebski V, Wolfram G, Reed N, Pignata S, Ferrero A, Brown C, Eisenhauer E, Pujade-Lauraine E. Health-related quality of life in recurrent platinum-sensitive ovarian cancer--results from the CALYPSO trial (ONLINE). Ann Oncol 2012.


Meta-Analysis that included data from Canadian Cancer Trials Group MA.4, MA.5 and MA.21:

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials. The Lancet 379: 432-44, 2012.

Meta-Analysis that included data from Canadian Cancer Trials Group MA.4:

Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effect of radiotherapy after breast-conserving surgery on 10-year recurrence and 15-year breast cancer death: meta-analysis of individual patient data for 10,801 women in 17 randomised trials. Lancet 378: 1707-16, 2011.